- Last Friday, FDA Law Blog wrote about yet another 180-day exclusivity letter from the FDA, this one requesting comment on the "failure to market" forfeiture provisions of the MMA.
- FDA Law Blog also posted a very nice summary of the FDA Amendments Act, which, among other changes, revises the citizen petition process.
- GSK sued the U.S. Patent & Trademark Office last Tuesday to block implementation of the PTO's new rules restricting patent claims and continuation applications. Read more here: Patent Docs; Patently-O; Pharmalot; WSJ Health Blog.
- The Wall St. Journal had an interesting article last week on China's generic drug industry. In case you're not a subscriber to the Journal, you can read the WSJ Health Blog's summary here or Pharmalot's here.
- On October 4, the FDA announced an initiative to streamline the generic drug approval process. GPhA reacted with skepticism.
Editor
About
- The Orange Book blog team are a group of attorneys with McAndrews, Held and Malloy, which is a full-service IP firm representing both brands and generics in various aspects of IP law. This blog does not provide legal advice. If you are seeking legal advice, please contact the author directly.
Disclaimer
- Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is not edited by McAndrews, Held & Malloy, Ltd. ("MHM") or its clients. The views expressed are solely those of the authors, and may not reflect the views of MHM or its clients. No part of Orange Book Blog--whether information, commentary, or other--may be attributed to MHM or its clients. MHM represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MHM clients. Orange Book Blog will always strive to be unbiased. All information on Orange Book Blog should be double-checked for its accuracy and current applicability.
Susbscribe
« Paddock Labs Prevails Over Schwarz Pharma in Univasc Case at Federal Circuit | Main | Federal Circuit Affirms Invalidity of Par Pharma's Patents on Megestrol Acetate Formulations »
October 15, 2007
The comments to this entry are closed.
Susbscribe
Search
Categories
- 180-Day Exclusivity (26)
- 271(e)(1) Safe Harbor (11)
- 271(e)(2) Jurisdiction (2)
- 30-Month Stay (3)
- Antitrust (49)
- Authorized Generics (20)
- Biosimilars (33)
- Citizen Petitions (22)
- Claim Construction (1)
- Claim Preclusion (1)
- Collateral Estoppel (2)
- Conferences (92)
- Declaratory Judgment Jurisdiction (25)
- FDA Announcements (7)
- FDA Litigation (12)
- Inequitable Conduct (4)
- Infringement--271(g) (1)
- Infringement--Direct (4)
- Infringement--Indirect (7)
- Inter Partes Review (6)
- Issue Preclusion (2)
- Orange Book Issues (27)
- Paragraph IV Cases (207)
- Patent Eligibility (2)
- Patent Term Extension (13)
- Pediatric Exclusivity (14)
- Pharma Business News (38)
- Preliminary Injunction (2)
- Prosecution (1)
- Section viii Statements (5)
- Validity--Novelty (6)
- Validity--Obviousness (22)
- Validity--Section 101 (2)
- Validity--Section 112 (6)
Comments